Table 3.

Estimates of the effect of sevelamer carbonate relative to calcium carbonate, adjusted for period of treatment

Variable	Estimate	95% Confidence Interval		P Value
		Lower	Upper
HbA1c	−0.67	−1.25	−0.10	0.02
Glucose	−35.4	−78.6	7.9	0.11
Total cholesterol	−14.58	−27.22	−1.94	0.02
HDL cholesterol	2.34	−3.00	7.68	0.39
LDL cholesterol	−9.96	−20.2	0.29	0.06
Triglycerides	−56.2	−107.7	−4.70	0.03
TNFα	−7.2	−11.01	−3.38	<0.001
8-isoprostanes	−103.8	−161.7	−46.0	<0.001
Serum carboxymethyllysine	−11.11	−16.22	−6.00	<0.001
Serum methylglyoxal	−0.55	−0.99	−0.11	0.01
Intracellular carboxymethyllysine	−2.43	−4.05	−0.82	0.003
Intracellular methylglyoxal	−0.48	−0.85	−0.11	0.01
AGER1	120.7	64.4	176.9	<0.001
SIRT1	93.0	35.2	150.7	0.002
Cystatin Ca	0.29	−0.02	0.60	0.07
Serum potassium	0.46	0.008	0.84	0.02
Serum chloride	2.90	1.10	4.70	0.002
Serum bicarbonate	−1.51	−3.83	0.82	0.21
Fibroblast growth factor 23	−59.74	−116.35	−3.12	0.04
Urine phosphate	0.07	−0.02	0.170	0.12
Urine protein/creatinine	−0.02	−0.45	0.41	0.92
Dietary phosphate	−20.62	−344.87	386.11	0.91

AGER1, advanced glycation end product receptor 1; SIRT1, sirtuin 1.

^aFirst period of observation analyzed only due to evidence of a period by treatment interaction.